Dr. Reddy's Laboratories Limited (DRREDDY): research summary

Price history, fundamentals, business-quality scores, DCF intrinsic value, shareholding, quarterly results and risk metrics for Dr. Reddy's Laboratories Limited, explained in plain English.

• ▪Dr. Reddy's Laboratories Limited is tracked in the Pharma & Healthcare sector of the NSE universe covered here.
• ▪DRREDDY closed at ₹1,345.00 on 29 October 2026.
• ▪Over the past year the shares are up 7.5%, trading between ₹1,101.00 and ₹1,414.90.
• ▪Reported fundamentals show return on equity of 7.34%, a net margin of 8.48%, debt to equity of 18.57.
• ▪Our transparent MaxGrade checklist scores it F (30/100) across momentum, growth, profitability and safety, using Pharma & Healthcare sector medians as the bar.
• ▪Annualised volatility over the past year is 24.16% with a maximum drawdown of -17.45% and a beta of 0.47 against NIFTY 50.
• ▪Recent coverage: Market wrap: Dr Reddys, JSW Steel, Shriram Finance, Tata Consumer top gainers and losers on Nifty and Sensex on Monday
• ▪Recent coverage: Dr Reddy's receives DCGI approval for esophageal cancer drug Zytorvi
• ▪Recent coverage: Pharma Q2 Outlook: Pricing pressure, US competition to weigh on select players

Other Pharma & Healthcare companies: Abbott India, Acutaas Chemicals, Ajanta Pharmaceuticals, Alkem Laboratories, Anthem Biosciences, Apollo Hospitals Enterprise, Aster DM Quality Care, Aurobindo Pharma

Last traded values from 29 Oct 2026. Market opens at 9:15 IST.